• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Akero Initiates Phase 2b HARMONY Study of Efruxifermin for NASH americanpharmaceuticalreview
    March 01, 2021
    Akero Therapeutics has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin (EFX), the company's lead product candidate for the treatment of NASH.
  • Akero Expands NASH Trial to Include Cohort of Cirrhotic Patients americanpharmaceuticalreview
    January 19, 2020
    Akero Therapeutics announced the ongoing Phase 2a BALANCED study of AKR-001 is being expanded to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.
  • Akero Announces Dosing of First Patient in NASH Study americanpharmaceuticalreview
    July 04, 2019
    Akero Therapeutics announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service